You are here: Industry Insights > Eleva

News List

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization PharmaSources
October 15, 2024
Eleva, a pioneer in unlocking difficult-to-produce biologics based on a breakthrough manufacturing platform, announced today the appointment of Dr. Elisabeth Lackner to its Supervisory Board.
Eleva Appoints Martin Bauer, MD as Chief Medical Officer Adding Substantial Clinical Development Expertise to the Organization Biotech Newswire
February 20, 2025
Eleva appoints Dr. Martin Bauer as CMO. Its Factor H (CPV - 104) program may enter clinic in 2025 for C3G, and dry AMD is a potential second indication.
Eleva Enters Clinical Development of Difficult-To-Express High-Potential Proteins prnasia
October 13, 2021
Eleva, a manufacturer of superior biologics, is entering clinical phases with its own drug candidates, such as immune-regulating factor H, as well as in collaboration with pharmaceutical partners.
Eleva Reaches Industrial Production Scale and Prepares for Clinical Development of Factor H prnasia
September 23, 2021
Eleva, a manufacturer of superior biologics, is scaling up its production capacity to 2500 l in state-of-the-art single-use reactors. This will produce enough factor H to cover all three clinical phases.
Eleva Drug Candidate Examined for Use in COVID-19 Treatment americanpharmaceuticalreview
June 15, 2020
Eleva is exploring the potential of one of its drug candidates for first-in-line therapy of COVID-19. The compound, factor H, is part of the complement system, which is believed to affect the severity of the course of COVID-19.
Eleva's Drug Candidate Examined for Use in COVID-19 Treatment americanpharmaceuticalreview
June 10, 2020
Eleva is exploring the potential of one of its drug candidates for first-in-line therapy of COVID-19. The compound, factor H, is part of the complement system, which is believed to affect the severity of the course of COVID-19.